drug adverse effects of gliptins

From Aaushi
Jump to navigation Jump to search
[1][2][3][4][5][6][7][8][9][10][11][12][13]

Adverse effects

* unfavorable adverse effect profile including anaphylaxis & pancreatitis[7]

More general terms

References

  1. ↑ 1.0 1.1 Singh S et al Glucagonlike Peptide 1-Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus. A Population-Based Matched Case-Control Study. JAMA Intern Med. 2013;():1-6. <PubMed> PMID: https://pubmed.ncbi.nlm.nih.gov/23440284 <Internet> http://archinte.jamanetwork.com/article.aspx?articleid=1656537
  2. ↑ 2.0 2.1 FDA MedWatch. August 28, 2015 DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm460238.htm
  3. ↑ 3.0 3.1 3.2 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
  4. ↑ 4.0 4.1 Li L, Li S, Deng K et al Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ 2016;352:i610 <PubMed> PMID: https://pubmed.ncbi.nlm.nih.gov/26888822 Free Article <Internet> http://www.bmj.com/content/352/bmj.i610
  5. ↑ 5.0 5.1 Tkac I, Raz I. Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care 2017 Feb; 40:284. <PubMed> PMID: https://pubmed.ncbi.nlm.nih.gov/27659407 <Internet> http://care.diabetesjournals.org/content/40/2/284
    DeVries JH, Rosenstock J. DPP-4 inhibitor-related pancreatitis: Rare but real! Diabetes Care 2017 Feb; 40:161 <PubMed> PMID: https://pubmed.ncbi.nlm.nih.gov/28108536 <Internet> http://care.diabetesjournals.org/content/40/2/161
  6. ↑ 6.0 6.1 Liu J, Li L, Deng K et al Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ. 2017 Jun 8;357:j2499. Review. PMID: https://pubmed.ncbi.nlm.nih.gov/28596247 Free PMC Article
  7. ↑ 7.0 7.1 7.2 Therapeutics Letter #108. Therapeutics Initiative Drugs to Avoid. http://www.ti.ubc.ca/2018/01/04/108-drugs-avoid/
  8. ↑ 8.0 8.1 Abrahami D, Douros A, Yin H, et al Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ 2018;360:k872 <PubMed> PMID: https://pubmed.ncbi.nlm.nih.gov/29563098 <Internet> http://www.bmj.com/content/360/bmj.k872
  9. ↑ 9.0 9.1 Abrahami D, Douros A, Yin H et al Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ 2018;363:k4880 PMID: https://pubmed.ncbi.nlm.nih.gov/30518618 https://www.bmj.com/content/363/bmj.k4880
  10. ↑ 10.0 10.1 10.2 Lee M et al. Nationwide trends in pancreatitis and pancreatic cancer risk among patients with newly diagnosed type 2 diabetes receiving dipeptidyl peptidase 4 inhibitors. Diabetes Care 2019 Nov; 42:2057 PMID: https://pubmed.ncbi.nlm.nih.gov/31431452 https://care.diabetesjournals.org/content/42/11/2057
  11. ↑ 11.0 11.1 Geriatric Review Syllabus, 10th edition (GRS10) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2019
  12. ↑ 12.0 12.1 Kitayama S, Makino T, Shimizu T. Dipeptidyl Peptidase 4 Inhibitor-Associated Bullous Pemphigoid. Mayo Clin Proc. 2025 Nov 3:S0025-6196(25)00396-9. PMID: https://pubmed.ncbi.nlm.nih.gov/41182204 https://www.mayoclinicproceedings.org/article/S0025-6196(25)00396-9/fulltext
  13. ↑ 13.0 13.1 Douros A, Rouette J, Yin H et al Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes. Diabetes Care. 2019 Aug;42(8):1496-1503. PMID: https://pubmed.ncbi.nlm.nih.gov/31182489
Retrieved from "https://aaushi.info/w/index.php?title=A379280&oldid=1283737"